Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.

ABSTRACT: SARS-CoV-2 infection, and resulting disease, COVID-19, has a high mortality amongst patients with haematological malignancies. Global vaccine rollouts have reduced hospitalisations and deaths, but vaccine efficacy in patients with haematological malignancies is known to be reduced. The UK-strategy offered a third, mRNA-based, vaccine as an extension to the primary course in these patients. The MARCH database is a retrospective observational study of serological responses in patients with blood disorders. Here we present data on 381 patients with haematological malignancies. By comparison with healthy controls, we report suboptimal responses following two primary vaccines, with significantly enhanced responses following the third primary dose. These responses however are heterogeneous and d

SUBMITTER: Cook LB 

PROVIDER: S-EPMC9662771 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature